Clinical trial TOTAL
A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance (TOTAL)
Cancers | |
---|---|
Organ | Non-Hodgkin lymphoma |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | Lysarc |
EudraCT Identifier | 2017-000409-19 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03496779 |
Inclusion criteria | CD30 positive Peripheral T-cell Lymphoma/Ann Arbor stage I-IV/at least 1 measurable lesion >=1,5cm |
Last update |